View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
  2. Company News
February 14, 2019

Innovent starts treatment in IBI101 monoclonal antibody trial

Chinese biopharmaceutical firm Innovent Biologics has started treating patients in a Phase I clinical trial of its monoclonal antibody candidate IBI101.

Chinese biopharmaceutical firm Innovent Biologics has started treating patients in a Phase I clinical trial of its monoclonal antibody candidate IBI101.

IBI101 is a recombinant fully human anti-tumour necrosis factor receptor superfamily member 4 (anti-OX40) monoclonal antibody, which is indicated for the treatment of advanced solid tumours.

Pre-clinical testing showed that the therapeutic could boost effector T cells activation and mediate clearance of regulatory T cells, helping to inhibit the growth of tumours.

An investigational new drug (IND) application for the product was approved by the US Food and Drug Administration (FDA) in December last year.

During the Phase I trial, the safety, tolerance and primary efficacy of IBI101 will be assessed when given as a single agent or in combination with Tyvyt (sintilimab).

“We are dedicated to exploring the most advanced research areas in cancer immunotherapy and providing innovative medicines.”

Sintilimab is an anti-programmed cell death protein 1 (PD-1) antibody jointly developed by Innovent and Eli Lilly.

The trail will enrol approximately 80 advanced solid tumour patients who did not experience adequate response to standard treatments.

Phase Ia of the trial saw eight dose levels of IBI101 evaluated, while the Ib portion will study four dose levels of the product in combination with sintilimab.

Innovent Biologics founder, CEO and chairman Michael Yu said: “We are dedicated to exploring the most advanced research areas in cancer immunotherapy and providing innovative medicines that improve lives around the world.

“The initiation of Phase I study of IBI101 and dosing of first patient have again demonstrated our efforts and commitment. We truly anticipate further breakthroughs so that more patients will potentially benefit in the future.”

The trial’s primary outcome measure is the incidence of adverse events, while its secondary measures include overall response rate, time to and duration of response, and progression-free survival.

It is expected to be completed by January 2022.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Clinical Trials Arena